Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FG-4592 (Roxadustat) in Non-Dialysis Chronic Kidney Disease Patients With Anemia
Brief Summary: The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.


Options:
A: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat, Drug: Iron | Arm Label: ESA (Erythropoiesis Stimulating Agent) treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa, Drug: Darbepoetin alfa, Drug: Iron | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Epoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment | Intervention Type: DRUG; Name: Iron; Assigned to Arm(s): ESA (Erythropoiesis Stimulating Agent) treatment, Roxadustat
B: Arm Label: Molidustat, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Arm Label: Molidustat, 160 mg; Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934), Drug: Placebo | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Molidustat, 120 mg, Molidustat, 160 mg, Molidustat, 40 mg, Molidustat, 80 mg
C: Arm Label: Cohort A: Roxadustat Tiered, Weight Based Dosing TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort C: Roxadustat at 50 mg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort D: Roxadustat at 100 mg TIW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Cohort F: Roxadustat at 70 mg BIW then QW; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Cohort A: Roxadustat Tiered, Weight Based Dosing TIW, Cohort B: Roxadustat Tiered, Weight Based Dosing TIW then BIW, Cohort C: Roxadustat at 50 mg TIW, Cohort D: Roxadustat at 100 mg TIW, Cohort E: Roxadustat Tiered, Weight Based Dosing BIW then QW, Cohort F: Roxadustat at 70 mg BIW then QW
D: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa

Answer: C